New hope for hemophilia a patients with inhibitors: PCC trial targets bleeding episodes

NCT ID NCT07406139

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a medicine called prothrombin complex concentrate (PCC) to stop bleeding episodes in people with hemophilia A who have developed inhibitors (antibodies that block standard treatment). Thirty participants aged 12 to 65 will receive PCC on-demand during bleeding, with doses adjusted based on bleeding type. The goal is to see how well and safely PCC controls bleeding within 24 hours.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: prothrombin complex concentrate (PCC)
What this could lead to: If successful, this could provide a reliable on-demand treatment option to stop bleeding episodes in people with hemophilia A who have inhibitors.
What could go wrong: This is a small, early-phase exploratory study with only 30 participants, so results may not apply to everyone. There is also a risk that PCC may not control bleeding effectively in all cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMOPHILIA INHIBITORS

Contacts and locations

Locations

Institute of haematology and Blood diseases hospital
RECRUITING

Tianjin, Tianjin Municipality, 300020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.